Home › Companies › RNTX

Rein Therapeutics

Market cap $30.7M 86.3M shares (10-Q, Nov 12, 2026) × $0.356 close Nov 17, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

10 trackedQuarter catalyst calendar →
  1. admilparant BMS Ph3 topline2H 2026admilparant BMS Ph3 topline, 2H 2026, material
  2. LTI-03 Ph2 interim4Q 2026LTI-03 Ph2 interim, 4Q 2026, notable
  3. LTI-03 topline2027LTI-03 topline, 2027, thesis-defining
  4. RENEW enrollment doneEarly 2027RENEW enrollment done, Early 2027, notable
  5. RNTX listing updateFeb 17, 2027RNTX listing update, Feb 17, 2027, routine
  6. Tyvaso nebulized PDUFA dateApr 2027Tyvaso nebulized PDUFA date, Apr 2027, material
  7. TETON-1/-2 United Therapeutics PDUFA dateApr 2027TETON-1/-2 United Therapeutics PDUFA date, Apr 2027, material
  8. ASPIRE Vicore Ph2b toplineMid-2027ASPIRE Vicore Ph2b topline, Mid-2027, material
  9. RNTX legacy warrants corporate updateMay 2027RNTX legacy warrants corporate update, May 2027, routine
  10. MIST Avalyn Ph2b topline2H 2027MIST Avalyn Ph2b topline, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Discontinued (2)

Capital (as filed)

Cash
$943K cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$35.5M Sep 30, 2026
Long-term investments
$994K Sep 30, 2026
Operating cash flow
−$7.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$36.5M cash, runway first quarter of 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Rein Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Rein Therapeutics (RNTX) — Scientific Deep Dive for LTI-03 and Pipeline Products Biology is real but the differentiating epithelial-regeneration mechanism has no significant human evidence, disclosure is selectively framed, and the Q4 2026 interim is arithmetically incapable of informing efficacy.
  2. Watch UPDATE: Rein Therapeutics (RNTX) - The Interim That Couldn't Speak Interim was blinded and uninformative on efficacy, but faster-than-expected enrollment pulls the real binary into 2027; drug is near cash value but reverse split and post-topline raise both look likely, so it stays on the watch list rather than a buy.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)